Treatment with interleukin-33 is non-toxic and protects retinal pigment epithelium in an ageing model of outer retinal degeneration by Clare, Alison J et al.
                          Clare, A. J., Copland, D. A., Nicholson, L. B., Liu, J., Neal, C. R.,
Moss, S., Dick, A. D., & Theodoropoulou, S. (2020). Treatment with
interleukin-33 is non-toxic and protects retinal pigment epithelium in
an ageing model of outer retinal degeneration. Journal of Cellular and
Molecular Medicine. https://doi.org/10.1111/jcmm.16000
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1111/jcmm.16000
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://doi.org/10.1111/jcmm.16000. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
J Cell Mol Med. 2020;00:1–5.    |  1wileyonlinelibrary.com/journal/jcmm
1  | INTRODUC TION
Age-related macular degeneration (AMD) is a degenerative disease 
of the eye and the leading cause of central vision loss. Characterized 
by drusen deposits, atrophy of the retinal pigment epithelium (RPE) 
and photoreceptor (PR) loss, AMD can progress into two stages of 
vision loss, acute neovascularization AMD (nAMD) and, in the major-
ity of patients, pernicious geographic atrophy (aAMD). Whilst nAMD 
can effectively be treated in most patients with VEGF-blocking 
agents, aAMD currently has no therapeutic options.1,2
Dysregulation of the immune system homeostasis is operative 
in the pathogenesis of AMD.2 We previously revealed a protective 
role for interleukin-33 (IL-33), in choroidal neovascularization and 
attenuation of wound healing.3 IL-33 is constitutively expressed in 
the RPE and Müller cells and acts as an ‘alarmin’ under necrotic cell 
death.3,4 Loss of endogenous IL-33 leads to chronic inflammation 
after retinal detachment.5 Conversely, under acute stress, endoge-
nous IL-33 released from Müller cells triggers an inflammatory re-
sponse and PR degeneration.4 The divergence in data needs to be 
reconciled to understand whether exogenous IL-33 intervention 
early in disease could promote homeostasis and repair.
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Abstract
The leading cause of central vision loss, age-related macular degeneration (AMD), 
is a degenerative disorder characterized by atrophy of retinal pigment epithelium 
(RPE) and photoreceptors. For 15% of cases, neovascularization occurs, leading to 
acute vision loss if left untreated. For the remaining patients, there are currently no 
treatment options and preventing progressive RPE atrophy remains the main thera-
peutic goal. Previously, we have shown treatment with interleukin-33 can reduce 
choroidal neovascularization and attenuate tissue remodelling. Here, we investigate 
IL-33 delivery in aged, high-fat diet (HFD) fed mice on a wildtype and complement 
factor H heterozygous knockout background. We characterize the non-toxic effect 
following intravitreal injection of IL-33 and further demonstrate protective effects 
against RPE cell death with evidence of maintaining metabolic retinal homeostasis 
of Cfh+/−~HFD mice. Our results further support the potential utility of IL-33 to 
prevent AMD progression.
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In this study, we use an insidious aAMD model, aged hetero-
zygous complement factor H knockout (Cfh+/−) mice on a high-fat 
diet (HFD)6 to determine the safety of IL-33 treatment and demon-
strate its potential as an early therapeutic for preventing AMD 
progression.
2  | METHODS
2.1 | Mice and in vivo experimental procedures
C57BL/6J mice (rd8−/−) were acquired from Charles River Laboratories 
(Margate, UK). Cfh−/− mice were backcrossed to C57BL/6J mice, es-
tablishing Cfh+/− mice within the University of Bristol Animal ser-
vices Unit. Procedures were performed according to University of 
Bristol institutional guidelines approved under Home Office Project 
License 30/3281, and the Association for Research in Vision and 
Ophthalmology (ARVO) statement.
Aged mice (80-99 weeks) were switched from normal diet to HFD 
(Envigo), for eight weeks.6 Administration of recombinant mouse 
IL-33 (ALX-522-101-C010, Enzo Life Sciences Ltd) or, in contralat-
eral eye, vehicle control (RPMI, 5% foetal calf serum; 0.5% penicil-
lin/streptomyocin; 0.5% L-glutamine; 0.5 mmol/L Sodium Pyruvate, 
2.5 ng/mL recombinant murine IL-3 [Thermo Fisher Scientific] and 
5 ng/mL recombinant murine SCF [Stem Cell Technologies]) was de-
livered by 2 µL intravitreal injection. In vivo imaging optical coher-
ence tomography (OCT) scans of retina were captured using Micron 




For whole-mounts, posterior eye cups were dissected and fixed in 
2% v/v formaldehyde overnight at 4°C. Retina and RPE/choroid were 
blocked in 5% w/v bovine serum albumin with 0.3% v/v Triton X-100 
(Sigma Aldrich) in PBS before staining with TMR Red-dUTP TUNEL 
(Roche Diagnostics), followed by incubation with ZO-1 antibody (1 
in 50; 40-2200; Thermo Fisher Scientific) overnight at 4°C. Tissue 
was then incubated with appropriate secondary antibody (A-11034; 
Invitrogen; 1 in 200) and mounted in hard-set medium (Vector 
Laboratories). Images were captured using a Leica SP5-AOBS confo-
cal laser scanning microscope (Leica Microsystems Ltd.) and TUNEL 
spots identified using Volocity® Image Analysis Software 6.0. Data 
are presented as mean number of TUNEL + cells per field of view 
(FOV).
2.3 | Electron microscopy
For transmission electron microscopy (TEM), eyes were fixed in 2.5% 
v/v glutaraldehyde initially at RT for 2 hours, before further fixing of 
posterior cup only at 4°C until processed. Eye cups were fixed in os-
mium tetroxide, stained with uranyl acetate and dehydrated through 
a graded ethanol series to 100% ethanol, before incubation with pro-
pylene oxide and infiltration with Epon resin. Eyes were then embed-
ded and polymerized at 60°C for 2 days. Thin sections (70-80 nm) were 
prepared and stained with lead and uranyl salts. Images were captured 
using a Tecnai T12 microscope (Thermo Fisher Scientific). Across four 
sections, 55-60 images were captured per eye and fifteen measure-
ments/image were made along the Bruch's membrane using FIJI.7
2.4 | Protein lysate and Western blots
Whole retinas were crushed in 200 µL Pierce® RIPA buffer (Thermo 
Fisher Scientific) with protease inhibitor (Cell Signalling Technologies) 
and samples were separated by SDS-PAGE before transfer to PVDF. 
Following blocking with 5% w/v milk in TBS + Tween 20 (0.1% v/v), 
blots were incubated with primary antibodies (all antibodies Cell 
signalling Technologies) Hexokinase II (2867; 1 in 1000) and β-actin 
(3700; 1 in 1000) at 4°C overnight. Protein was detected with HRP-
conjugated secondary antibody, anti-rabbit (1 in 2000) or anti-mouse 
(1 in 2000) and chemiluminescent (GE Healthcare). Densitometry 
was performed using FIJI.7
2.5 | Statistics
Analysis of data used three-way ANOVA in R studio (R version 3.6.1; 
RStudio, Inc) with independent factors, treatment, genotype and 
animal (accounting for paired eyes). A Tukey multiple comparisons 
test was used where significant effects were found. If no signifi-
cance was identified from further multiple comparisons, the result 
of three-way ANOVA is presented to demonstrate significant effect 
of independent factor. Mean sub-RPE deposits were analysed using 
a paired t test in GraphPad Prism (version 8.1.2; GraphPad Software 
Inc). All data are expressed as ± SEM.
3  | RESULTS AND DISCUSSION
The Cfh+/−~HFD model presents with distinct disease phenotype, 
without significant cell loss,6 providing opportunity to measure treat-
ment toxicity and efficacy in a mimic of early/intermediate aAMD. 
For analysis of IL-33 treatment in this model, we first assessed a non-
toxic dose, based on efficacious treatment doses.3 Animals received 
a weekly delivery of 1 ng/µL IL-33 or vehicle control, from the fifth 
week of HFD (Figure 1A). With acute models of retinal degeneration, 
release of endogenous IL-33 leads to significant retinal thinning.4 
Here, retinal thickness at week 8 was unaffected by IL-33 treatment in 
control C57BL/6 ~ HFD and Cfh+/−~HFD animals (Figure 1B,D), with 
thickness remaining similar to eyes pre-manipulations (Figure 1A-C).
We further determined IL-33 toxicity by TEM analysis of sub-
RPE deposits, a key pathological feature in the Cfh+/−~HFD 
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model.6 Here, we observed deposits in vehicle and IL-33-treated 
Cfh+/−~HFD eyes (Figure 1E), with no difference in mean height 
(n = 3, 3, Figure 1F). Deposit formation in AMD is considered to be 
driven by a dysregulated immune response and local inflammation.8 
Toxicity was not apparent as no exacerbation of pathological deposit 
formation was observed with IL-33 treatment.
Sub-RPE deposits in Cfh+/−~HFD mice are thought to drive comple-
ment-mediated monocytosis and cytotoxicity, resulting in subsequent 
RPE damage and atrophy.6 Indeed, activated monocytes and pro-inflam-
matory cytokines can induce reactive oxygen species (ROS) production 
and cell death in RPE.9 Multiple comparisons did not reveal significant 
difference in extent of cell death between C57BL/6 ~ HFD vehicle eyes 
and any other group. Notwithstanding, there was a significant increase in 
cell death in the RPE of vehicle-treated Cfh+/−~HFD eyes, compared to 
C57BL/6 ~ HFD IL-33-treated eyes (Figure 2A-B). The rescue of cell death 
in Cfh+/−~HFD animals with IL-33 was to levels found in C57BL/6 ~ HFD 
F I G U R E  1   Exogenous IL-33 is non-toxic in aged C57BL/6 ~ HFD and Cfh+/−~HFD mice. (A) Schematic to explain timeline of animal 
manipulations; TEM—transmission electron microscopy, IHC—immunohistochemistry, WB—Western blot (B) OCT scan of eyes from 
Cfh ± and C57BL/6 mice prior to high-fat diet (HFD) and post-HFD animals injected with either vehicle or IL-33 (1 ng/µL). Scale bars are both 
100 µm. Graph to show retinal thickness measured from OCT scans of Cfh± (n = 4) and C57BL/6 mice prior to high-fat diet start (n = 6) (C) 
or Cfh+/−~HFD or C57BL/6 ~ HFD mice injected with either IL-33 or vehicle control (n = 4-11) (D). (E) Transmission electron micrograph 
images of sub-RPE deposit in Cfh+/−~HFD mice treated with either IL-33 (1 ng/µL) or vehicle. Arrowhead shows remnants of basal infoldings 
disrupted by deposit formation. In both IL-33 and vehicle-treated eyes, large numbers of vesicle-like structures with an electron-dense shell 
are observed within the deposits, as indicated by the asterix (*). BrM—Bruch's membrane. Scale bar is 2 µm. (F) Graph shows mean deposit 
height in eyes of Cfh+/−~HFD IL-33 and vehicle-treated eyes (n = 3 of each)
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eyes (Figure 2B). As IL-33 treatment did not affect deposit formation, it 
supports protection of RPE is through re-balancing of any pro-inflamma-
tory responses or protection from ROS. Certainly, IL-33 promotes a skew 
to a protective non-inflammatory type 2 immune response in EAU and 
CNS injury.10,11 Additionally, our previous work has found IL-33 signalling 
via ST2 promotes normal bioenergetic source of oxidative phosphoryla-
tion (OXPHOS) in RPE, protecting from oxidative stress. TLR-stimulation 
of RPE induces a switch to glycolysis, essential to subsequent pro-inflam-
matory cytokine release.12 IL-33 promotion of RPE metabolic homeosta-
sis would negate any pro-inflammatory effect during stress conditions, 
protecting RPE from cell death.
Another indicator of disease is loss of photoreceptors. Analysis 
of cell death in retina flatmounts revealed a significant genotype and 
model effect with higher TUNEL-positive cells in all Cfh+/−~HFD an-
imals compared to all C57BL/6 ~ HFD. No treatment effect was ob-
served (Figure 2A,C). In aAMD, loss of RPE precludes significant PR 
loss.13 Whilst there is no effect of IL-33 treatment on cell loss in the 
retina early in the course, the RPE protection conferred is predicted 
to prevent cell loss with time.
To further investigate the potential impact for IL-33 protection of 
RPE on retinal health and support the metabolic regulatory role,12 we 
employed Hexokinase II (HKII). The energetically demanding retina 
relies on aerobic glycolysis, for which HKII is an essential mediator.14 
Conversely, RPE utilizes lactate for OXPHOS; however, in the con-
text of mitochondrial oxidative stress, RPE can become more glyco-
lytic, starving the retina of its energy source.15 Here, in Cfh+/−~HFD 
F I G U R E  2   IL-33 treatment protects against RPE cell death and loss of metabolically important protein Hexokinase II in retina in 
Cfh+/−~HFD mice. A, Confocal images of ZO-1/TUNEL stained RPE/choroid and DAPI/TUNEL stained retina flatmounts from Cfh+/−~HFD 
and C57BL/6 ~ HFD eyes treated with either vehicle or IL-33 (1 ng/µL). Scale bar is 38 µm. B, Quantitative analysis of mean TUNEL + cells 
per field of view in RPE/choroid flatmounts. A significant reduction in cell death is observed in Cfh+/−~HFD IL-33-treated eyes (n = 9) 
compared to Cfh+/−~HFD vehicle-treated eyes (n = 9; **P = .0037) and C57BL/6 ~ HFD IL-33-treated eyes (n = 5; *P = .040). C, Quantitative 
analysis of TUNEL + cells per field of view in retina. Cell death was significantly increased in Cfh+/−~HFD eyes (n = 7, 7) compared to 
C57BL/6 ~ HFD control (n = 4, 5), irrespective of treatment (*P = .032). D, Representative Western blot of Hexokinase II (HKII) protein 
expression in retina lysates, cropped lanes from the same blot. E, Densiometric analysis demonstrates HKII is significantly reduced in 
Cfh+/−~HFD vehicle-treated eyes (n = 9) compared to Cfh+/−~HFD IL-33 (1 ng/µL; n = 9), C57BL/6 ~ HFD veh (n = 5) and IL-33 (1 ng/µL; 
n = 5)-treated eyes (*P = .017, P = .010 and P = .039, respectively)
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vehicle control retina lysates we observed significant loss of HKII 
compared to C57BL/6 ~ HFD vehicle and C57BL/6 ~ HFD IL-33-
treated retinas (Figure 2D; Supplementary Information). IL-33 treat-
ment in Cfh+/−~HFD retinas significantly recovered HKII expression 
to levels similar in C57BL/6 eyes (Figure 2E), supporting IL-33 treat-
ment maintenance of metabolic homeostasis.
Our results demonstrate a non-toxic effect for exogenous IL-33 
treatment in aged mice. Moreover, we reveal a protective capability of 
IL-33 against RPE loss and for retina metabolic homeostasis in a dysreg-
ulated immune-mediated insidious model of outer retinal degeneration 
(Cfh+/−~HFD animals). Together, these data highlight the potential of 
IL-33 treatment to protect during early pathogenesis of AMD.
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